What’s New in the CTN?
Updates from the NIDA National Drug Abuse Treatment Clinical Trials Network. Want to share some news about your protocol, node, publications or presentations, or other CTN-related work here and/or in the CTN Bulletin? Email us at ctnlib@uw.edu!
New in the CTN Library (July-August 2023)
This post will contain a running list of all items added to the CTN Dissemination Library in July-August 2023. Castillo F, et al. Risks of Returning to Opioid Use at Treatment Entry and Early in Opioid Use Disorder Treatment: Role of Non-Opioid Substances. Drug and Alcohol Dependence 2023 (in press). CTN-0027, CTN-0030, CTN-0051 Parchman ML, et al. Supporting Practice Facilitators in a Learning Health Care System [commentary]. Permanente Journal 2023:23.035 Kidd JD, et al. Sexual Orientation Differences Among Men in a Randomized Clinical Trial of Extended-Release Naltrexone and Bupropion for…
Update on CTN-0100 (RDD)
In June, the CTN-0100 Project Team launched a month-long BINGO challenge aimed at boosting recruitment and retention across the 18 study sites. BINGO squares included hitting (or exceeding!) randomization targets for the month, reuniting with a missing participant, completing two randomizations in one day, and establishing a relationship with a new referring partner. The Operation PAR site (pictured) from the Florida Node Alliance was the first site to “BINGO,” just 6 days into the challenge! Five additional sites achieved “BINGO” by the end of the month. We thank all of…
Recording available for June’s CTN Webinar on FDA Basics & Essential Regulatory Compliance
New webinar recording available: Research 101 Session 2: FDA Basics & Essential Regulatory Compliance Description:This webinar outlines the basics of FDA oversight and reviews other essential regulatory activities to successfully keep a study in compliance, including ongoing management and reporting requirements. The regulatory portion reviews essential regulatory activities, such as IRB approvals and informed consent requirements. Lastly, there is a discussion of current challenges and best practices when working on regulatory compliance. Check out the recording here! Posted July 7, 2023
NIH Research Opportunity Announcements for N CREW Program (due Nov 1)
NIH has published two Research Opportunity Announcements (ROAs) for the HEAL-funded Native Collective Research Effort to Enhance Wellness (N CREW) Program, available on the N CREW Website. Applications are due Nov 1. Questions about this opportunity can be directed to NCREW@nih.gov. Additional information is also available on the N CREW Website. For more information, a Technical Assistance webinar will be held on Thursday, July 27th from 12:00 – 1:30 pm ET (click here to register). We encourage you to send any questions or comments about the ROAs and/or application process in advance of the webinar by emailing ncrew@nih.gov….
Science of D&I Conference: Call for Abstracts Open
AcademyHealth and the National Institutes of Health are once again convening the growing D&I science community for the 16th Annual Conference on the Science of Dissemination and Implementation in Health. The 16th Annual Conference theme is “Raising Expectations for D&I Science: Challenges and Opportunities”. The abstract solicitation and conference structure have been designed to focus our thinking and discussion on the highest priorities for dissemination and implementation science now and in the future to help optimize health and health care in the U.S. and globally. Does this sound like your work? Submit…
NIDA HIV Seminar Series: Ending the HIV Epidemic in the U.S. (July 26, 1pm ET)
Join the NIDA HIV Research Program in welcoming Bohdan Nosyk, PhD, Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at Simon Fraser University, for the next installment of the NIDA HIV Seminar Series titled “Ending the HIV/AIDS Epidemic in the US: How Do We Intervene to Meet Our Ambitious Goals?” Bohdan Nosyk is an Associate Professor and St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research at the Faculty of Health Sciences, and leads the Health Economic Research Unit at the Center for Health Evaluation & Outcome Sciences….
NIDA Racial Equity Initiative: Notices of Funding Opportunities (NOFOs)
These NOFOs are focused on research to advance equity for racial and/or ethnic minority populations in the United States. The NOFOs call for innovative, solution-oriented, community-engaged research from research teams with a commitment to broad dissemination of findings. Applications are expected to incorporate diverse perspectives. Please note that some NOFOs are open to all institutions, and some are limited to applications from Minority Serving Institutions (see Section III of the respective NOFOs for eligibility criteria). A recording of the TA webinar that was held on September 26, 2022, during which…
New in the Library: May 2023
May 1-31, 2023 Here are the newest items added to the Library in May 2023:
Big South/West Node Workshop at TxSUS 2023
The PIs of the CTN Big South/West Node attended this year’s Texas Substance Use Symposium (TxSUS) for a panel titled, “Screening, Interventions and Collaborative Care Models for Increasing SUD Treatment in Primary Care.” The panel session provided an overview and rationale of establishing primary care models for screening and interventions for SUD. The main objectives were to learn about (1) approaches for incorporating alcohol and drug screening into primary care practices, integrated with the electronic health record (EHR); (2) lessons learned from SUD collaborative care trials in primary care settings;…
Job Opening: Health Scientist Administrator at NIDA Center for the CTN
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) is seeking candidates for Health Scientist Administrator (Program Officer GS-12/13/14) positions. The incumbents will provide scientific leadership and collaborate with NIDA Clinical Trials Network (CTN) investigators in the conception, design, development, conduct, and monitoring of clinical trials and other research studies, as well as guidance and assistance in the dissemination of research findings. Desired qualifications for candidates include expertise in behavioral, pharmacological, or integrated therapies for substance use/substance use disorders, experience in the management of clinical trials, and expertise in…
News from the New England Consortium Node
NIDA News Release Buprenorphine initiation in the ER found safe and effective for individuals with OUD who use fentanyl. NIDA News, March 30, 2023. Referencing findings: D’Onofrio G, Hawk KF, Perrone J, et al. Incidence of Precipitated Withdrawal During a Multisite Emergency Department–Initiated Buprenorphine Clinical Trial in the Era of Fentanyl. JAMA Netw Open. 2023;6(3):e236108. doi:10.1001/jamanetworkopen.2023.6108 New Publication Kropp FB, Smid MC, Lofwall MR, Wachman EM, Martin PR, Murphy SM, Wilder CM, Winhusen TJ. Collaborative care programs for pregnant and postpartum individuals with opioid use disorder: Organizational characteristics of sites participating in the NIDA CTN0080…
New in the Library: March & April 2023
March-April 2023 Here are the newest items added to the Library in March and April 2023: Collaborative Care Programs for Pregnant and Postpartum Individuals with Opioid Use Disorder: Organizational Characteristics of Sites Participating in the NIDA CTN0080 MOMs Study. Kropp FB, et al. Journal of Substance Use and Addiction Treatment 2023;149:209030. CTN-0080 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A Stepped Wedge Hybrid Type 1 Effectiveness-Implementation Study. Greiner MG, et al. Contemporary Clinical Trials 2023 (in press). CTN-0097 Optimizing Recruitment and Retention in Substance Use Disorder Research in…
News from the Western States Node
CTN Western States Node investigators Dan Hartung and Elizabeth Waddell recently published findings from their CDC-funded project, Reducing Overdose After Release from Incarceration (PI: Waddell) that demonstrate risk of fatal and non-fatal opioid overdose risk is 10x greater among Oregon adults releasing from prison than in the state’s general population. Risk is even higher among women, those with documented substance use disorder and mental health treatment needs, and in the two weeks post release. Read the article in JSAT here. These findings are already driving policy discussions in Oregon and were…
Webinar: The Greater Intermountain Node (GIN): Where We Were, Where We Are, and Where We Will Be (April 18, 12pm MT)
Presenter: Adam J. Gordon, MD, MPH, FACP, DFASAMApril 18, 2023 | 12:00-1:00 PM MST In this presentation, Dr. Gordon will describe the origination, present status, and future opportunities of the CTN Greater Intermountain Node (GIN). He will describe the mission and aims of GIN, as well as the three studies originating from the Node and six studies hosted by it. Dr. Gordon will emphasize the remarkable research and clinical collaboration across the University of Utah campus and greater Intermountain area. He will also discuss the robust mentored training of the…
CTN Youth SIG Webinar: Getting Evidence-Based Treatments to Youth and Families Who are Involved in the Juvenile Legal System (May 19, 11am ET)
The CTN Youth SIG is pleased to invite you to an upcoming presentation/webinar: Getting Evidence-Based Treatments to Youth and Families Who are Involved in the Juvenile Legal System Ashli J. Sheidow, PhD, Senior Research Scientist, Oregon Social Learning CenterFriday, May 19th, 2023 (11:00 a.m.–12:00 p.m. ET) Dr. Sheidow’s services research examines methods and tools for getting substance use interventions to youth with juvenile legal system involvement. She will present lessons learned, with a focus on a task-shifting study with juvenile probation officers delivering contingency management treatment to youth and their parents/caregivers. The…
NEWS: US FDA approves Narcan (4mg naloxone nasal spray) for over-the-counter purchase/use
(From the US FDA press release) Today, the U.S. Food and Drug Administration approved Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription, use – the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. Today’s action paves the way for the life-saving medication to reverse an opioid overdose to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations,…
Protocol Update: CTN-0139
March 15, 2023 CTN-0139, the Collaborative Care for Polysubstance use in Primary Care Settings (Co-Care) Trial, is studying a collaborative care intervention for polysubstance use involving opioids and/or stimulants, in adult primary care patients. Collaborative care is a team-based approach to managing chronic conditions that has been effective for depression and other behavioral health conditions, and has the potential to transform the delivery of substance use treatment in primary care settings. This HEAL-funded CTN trial will test the Co-Care model versus enhanced usual care to reduce substance use and improve…
Recording Available: Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future
The Office of Research Training, Diversity, and Disparities is offering a series titled Profiles of Excellence: Focus on Diversity. This webinar, held on March 6, 2023 from 4-5pm EST, featured Ayana Jordan, MD, PhD, of NYU Grossman School of Medicine, talking about “Cultural Considerations for Addiction Research: Looking to the Past to Inform the Future.” View the recording here. (Passcode: Yyr!6b?j)
Webinar: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD (April 6, Northeast Node)
Join the CTN Northeast Node on April 6, 2023 (12pm-1pm ET) for the latest in their Science Series: Injectable XR Buprenorphine: A Better Mousetrap or a Paradigm Shift in MOUD? with Eva Quirion, NP, PhD This presentation will explore the science behind extended release (XR) buprenorphine and field experiences in the use of XR buprenorphine in a primary care setting. This talk will also address ways to bring this medication to patients and if this treatment makes financial sense. 1.0 AMA PRA Category 1 CME available! Join the Zoom meeting here (no…